Trial Profile
Pharmacogenetics of Gemtuzumab Ozogamicin (GO) Therapy in Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2023
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- 13 Dec 2022 Results assessing the retrospective impact of an updated risk classification on treatment allocation for de novo AML, by deriving samples from NCT01407757 and NCT01371981 , presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 01 Aug 2022 LASSO regression modeling was used to develop a 10-gene DNA damage response gene expression score (CalDDR-GEx10) predictive of clinical outcome in pediatric AML patients treated with treatment regimen containing GO from the AAML03P1 and AAML0531 trials, published in the Leukemia.
- 14 Dec 2021 Results assessing the CREBBP variant status in patients with AML enrolled on 4 successive COG trials for de novo pediatric AML (NCT00003790, NCT00070174, NCT01407757, NCT01371981), presented at the 63rd American Society of Hematology Annual Meeting and Exposition.